최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0071610 (2016-03-16) |
등록번호 | US-9669162 (2017-06-06) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 1166 |
Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification fa
Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.
1. A method of improving diabetes management with an electronic analyte monitoring and management system comprising a sensor, one or more processing units, and an infusion device, the method comprising: continuously or semi-continuously monitoring, using the sensor, an analyte level of a user, where
1. A method of improving diabetes management with an electronic analyte monitoring and management system comprising a sensor, one or more processing units, and an infusion device, the method comprising: continuously or semi-continuously monitoring, using the sensor, an analyte level of a user, wherein the monitoring occurs during a time segment in which a medication was administered to the user according to a first medication delivery profile;determining, using the one or more processing units, a frequency of an analyte level deviation during the time segment;determining, using the one or more processing units, a second medication delivery profile for administration of the medication during the time segment when the frequency of the analyte level deviation exceeds a threshold; andadministering the medication with the infusion device according to the second medication delivery profile such that the frequency of the analyte level deviation is reduced. 2. The method of claim 1, further comprising: outputting a notification associated with the second medication delivery profile; andafter outputting the notification, receiving an indication of acceptance of the second medication profile prior to administering the medication with the infusion device according to the second medication delivery profile. 3. The method of claim 1, wherein the first medication delivery profile is a first basal medication delivery profile, the second medication delivery profile is a second basal medication delivery profile, and wherein the method comprises: administering a bolus medication dose; anddetermining, using the one or more processing units, the second basal delivery profile by converting the bolus medication dose into the second basal delivery profile. 4. The method of claim 1, wherein determination of the second medication delivery profile occurs each time a bolus medication dose is administered. 5. The method of claim 1, wherein the first medication delivery profile is a first basal medication delivery profile, the second medication delivery profile is a second basal medication delivery profile, and wherein the method comprises determining, using the one or more processing units, the second basal delivery profile by adjusting a loop gain applied to the first basal medication delivery profile. 6. The method of claim 5, wherein the analyte level deviation is a first analyte level deviation, the method comprising: continuously or semi-continuously monitoring, using the sensor, an analyte level of the user, wherein the monitoring occurs during a period of time in which medication was administered to the user according to the second basal medication delivery profile;determining, using the one or more processing units, a second analyte level deviation during the period of time; anddetermining, using the one or more processing units, a third basal medication delivery profile for administration of the medication. 7. The method of claim 1, wherein the analyte level deviation is a glucose excursion. 8. The method of claim 1, wherein the analyte level deviation is a deviation from a target glucose mean. 9. The method of claim 1, further comprising determining a magnitude of the analyte level deviation, wherein determining, using the one or more processing units, the second medication delivery profile comprises modifying the first basal delivery profile in proportion to the magnitude of the analyte level deviation. 10. The method of claim 1, wherein determination of the second medication delivery profile occurs when the frequency of the analyte level deviation exceeds a threshold as measured over a plurality of days. 11. An apparatus, comprising: an infusion device adapted to administer a medication to a user according to instructions from one or more processing units;a sensor adapted to continuously or semi-continuously sense an analyte level of the user; the one or more processing units operatively coupled with the infusion device and the sensor; anda data storage unit operatively coupled to the one or more processing units, the data storage unit having stored therein executable programming instructions which, upon execution, cause the one or more processing units to: determine a frequency of an analyte level deviation during a time segment;determine a second medication delivery profile for administration of the medication during the time segment when the frequency of the analyte level deviation exceeds a threshold; andcause administration of the medication by the infusion device according to the second medication delivery profile such that the frequency of the analyte level deviation is reduced. 12. The apparatus of claim 11, wherein the executable programming instructions, upon execution, further cause the one or more processing units to: cause the output of a notification associated with the second medication delivery profile; andprocess an indication of acceptance of the second medication profile before causing administration of the medication with the infusion device according to the second medication delivery profile. 13. The apparatus of claim 11, wherein the first medication delivery profile is a first basal medication delivery profile, the second medication delivery profile is a second basal medication delivery profile, and wherein the executable programming instructions, upon execution, further cause the one or more processing units to determine the second basal delivery profile by conversion of an administered bolus medication dose into the second basal delivery profile. 14. The apparatus of claim 11, wherein the executable programming instructions, upon execution, further cause the one or more processing units to determine the second medication delivery profile each time a bolus medication dose is administered. 15. The apparatus of claim 11, wherein the first medication delivery profile is a first basal medication delivery profile, the second medication delivery profile is a second basal medication delivery profile, and wherein the executable programming instructions, upon execution, further cause the one or more processing units to determine the second basal delivery profile by adjusting a loop gain applied to the first basal medication delivery profile. 16. The apparatus of claim 15, wherein the analyte level deviation is a first analyte level deviation, and wherein the executable programming instructions, upon execution, further cause the one or more processing units to: determine that a second analyte level deviation occurred during a period of time in which medication was administered to the user according to the second basal medication delivery profile; anddetermine a third basal medication delivery profile for administration of the medication. 17. The apparatus of claim 11, wherein the analyte level deviation is a glucose excursion. 18. The apparatus of claim 11, wherein the analyte level deviation is a deviation from a target glucose mean. 19. The apparatus of claim 11, wherein the executable programming instructions, upon execution, further cause the one or more processing units to: determine a magnitude of the analyte level deviation; anddetermine the second medication delivery profile at least in part by a modification to the first basal delivery profile in proportion to the magnitude of the analyte level deviation. 20. The apparatus of claim 11, wherein the executable programming instructions, upon execution, further cause the one or more processing units to determine the second medication delivery profile when the frequency of the analyte level deviation exceeds a threshold as measured over a plurality of days.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.